Search Scholars Central
Articles, journals and conferences in one search. An exact title, DOI or ISSN is listed first.
Advanced searchHide advanced search
In the search box: "exact phrase" · -leave out · OR · prefix* · title: author: journal:
Opinion · 1 Mar 2023 Case report · 2013 Ectopic G-Csf Production by Malignant Plasma Cells in Patients with Diagnostic Criteria of Chronic Neutrophilic Leukemia
Chronic Neutrophilic Leukemia (CNL) is a relatively uncommon myeloproliferative neoplasia. Its diagnosis
Editorial · 18 Mar 2022 Editorial Note on Plasma Cell Leukemia
forceful type of these dyscrasias, establishing 2%to 4% of all instances of plasma cell malignancies. PCL might present as essential plasma cell leukemia, for example in patients without earlier
Short communication · 2021 The significance of membrane glycoproteins on the outcome of multiple myeloma
myeloma (MM) is an incurable hematological malignancy characterized by the clonal proliferation of malignant plasma cells in bone marrow, bone lesions, renal failure and immunodeficiency. The certain impact…
Mini review · 7 Mar 2022 A Review on Plasma Cell Leukemia
plasma cell dyscrasia, or a disease characterized by the malignant degeneration of plasma cells, a type of white blood cell. It is the most advanced and dangerous ... stage of these dyscrasias, accounting for 2% to 4%…
Case report · 2017 Primary Plasma Cell Leukemia Presenting as Heart Failure: A Case Report
cell leukemia (PCL) is an uncommon and aggressive plasma cell dyscrasia characterized by malignant plasma cells in bone marrow and peripheral blood. The prognosis of PCL patients treated with conventional
Review article · 26 Apr 2019 Cure of Primary Plasma Cell Leukemia by Tandem Autologous HSCT Followed by Maintenance Therapy
Plasma cell leukemia is an aggressive hematologic malignancy with rapidly progressive course and poor clinical outcome. It requires aggressive induction therapy followed by allogeneic hematopoietic stem cell…
Editorial · 2014 The MET Receptor Tyrosine Kinase as a Therapeutic Target in Multiple Myeloma
progressive and debilitating B-cell disorder typified by the accumulation and dissemination of malignant plasma cells in the bone marrow which subsequently induce osteolytic lesions.Despite recent advancement of new…
Conference abstract · 29 Nov 2011 A model of tumor dormancy in luminal a breast cancer
Multiple myeloma (MM) is hematologic malignancy characterized by the accumulation of malignant plasma cells in the bone marrow. Th e disease initially responds to alkylating agents, corticosteroids, and thalidomide…
Conference abstract · 29 Nov 2011 A novel non-viral gene vector using a combination of modifi ed HIV-1 Tat peptide with cationic lipids
Multiple myeloma (MM) is hematologic malignancy characterized by the accumulation of malignant plasma cells in the bone marrow. Th e disease initially responds to alkylating agents, corticosteroids, and thalidomide…
Conference abstract · 29 Nov 2011 Understanding therapy resistance in mutiple myeloma
Multiple myeloma (MM) is hematologic malignancy characterized by the accumulation of malignant plasma cells in the bone marrow. Th e disease initially responds to alkylating agents, corticosteroids, and thalidomide…
Research article · 2016 TMEM4 is Highly Expressed in Plasma Cell Neoplasms and Associated with B Lymphocyte Differentiation
identifybiomarkers for plasma cell neoplasms, we analyzed gene expression profile and proteomic characteristics of mouse models of plasmacytomas along with other types of B-cell neoplasms. We found that transmembrane…
Case report · 27 Sep 2022 Challenges in the Diagnosis of Plasma Cell Neoplasm with Idiopathic Amyloid-Like Deposits: A case Report with the Review of Literature
with poorer prognosis. It is characterized by the inability of the malignant plasma cells to produce heavy chains and resulting in the exclusive production of light chains. We present
Research article · 5 Jul 2017 CXC Chemokine ligand 12 (CXCL12) mediates multiple myeloma cell line (RPMI 8226) chemotxis via PLC 3, PI3K/AKT, RhoA, NFkB and ERK1/2
multiple myeloma (MM) blood-borne malignant plasma cells home to bone marrow (BM), where they accumulate in close contact with stromal cells. Nevertheless, the mechanisms responsible for MM cell chemotaxis
Conference abstract · 29 Oct 2018 Prognosis and response to therapy can be efficiently predicted by a combination of cytogenetic aberrations, detected by interphase-FISH in newly diagnosed multiple myeloma patients
Introduction: Multiple myelomas (MM) is a cytogenetically heterogenous plasma cell malignancy. The detection and interpretation of cytogenetic abnormalities in MM is of critical importance for prognosis and risk…
Short communication · 21 Aug 2022 The Cytokines in Endocrine Dysfunction of Plasma Cell Disorders
from the point of view of an endocrinologist. Plasma cell disorders are characterized by disproportionate proliferation of single clones of B cells that give rise to both structurally and electrophoretically…
Conference abstract · 24 Apr 2017 Microfluidic platforms for isolating tumor cells from blood samples
sensitivity and selectivity for innovative single cell analysis platforms. This talk will highlight our efforts in developing a microfluidic device for isolating plasma ... CTCs from multiple myeloma (MM) blood samples…
Commentary · 26 Jul 2022 Plasma Homocysteine and mental capability in older patients with immunological disorders.
treated early. The older populace is expanding and postpones in analysis of plasma cell malignancies are successive among them. Hyperglobulinemia of various myelomas (MM) assumes a part in hyper viscosity ... uncovered…
Conference abstract · 21 Sep 2018 Cytogenetic alterations detected by interphase-Fish, help in risk stratification and predicting therapy response in newly diagnosed multiple myeloma patients: A study of 342 cases
Introduction: Multiple myeloma (MM) is a cytogenetically heterogeneous plasma cell malignancy. The detection and interpretation of cytogenetic abnormalities in MM is of critical importance for prognosis and risk…
Research article · 2013 Multiple Myeloma: The Role of Angiogenesis in Disease Progression
myeloma and has a prognostic value in this disease. Multiple myeloma is a plasma cell malignancy that home to and expand in the bone marrow where actively interacts with stromal ... myeloma cells and the recruitment and…
Commentary · 5 Nov 2024 Liquid Tumors at a Glance: Innovations, Challenges and Future Directions in Hematologic Oncology
Hematologic malignancies, commonly referred to as liquid tumors, encompass a diverse group of cancers such as leukemias, lymphomas, and myelomas. Defined by unique genetic, molecular, and clinical characteristics, these…
Article · 3 Aug 2020 HOTAIR lncRNA expression can be a marker for disease activity and prognosis in multiple myeloma
addition, higher HOTAIR expression levels were seen in patients with higher percentage of malignant plasma cells (≥ 50 versus < 50%) in bone marrow (2.29±0.67 and 3.97±1.60 respectively
Research article · 24 Jan 2018 Value of long chain non-coding rnacrnde-h and gas5 in predicting the prognosis of multiple myeloma
Background: Multiple myeloma (MM) is a bone marrow malignant plasma cell disease characterized by focal bone lesions, soft tissue lesions and diffuses bone marrow infiltration. The purpose of this study
Review article · 22 Jul 2016 Current treatment options for elderly patients with multiple myeloma: clinical impact of novel agents
Multiple myeloma is a plasma cell malignancy that typically affects older individuals, with a median age of presentation being 67–70 years. The treatment paradigms for myeloma have changed dramatically

